Targeting drug-resistant cancer cells to improve treatment outcomes
Project 3
This study is looking at patients with advanced non-small cell lung cancer who have certain genetic changes, and it aims to find ways to target stubborn cancer cells that survive treatment and can make the cancer harder to treat, with the hope of improving current therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10891399 on NIH RePORTER |
What this research studies
This research focuses on advanced non-small cell lung cancer patients whose tumors have specific genetic mutations. It aims to understand and target a small population of drug-tolerant persister (DTP) cells that survive initial treatments and can lead to drug resistance. By identifying the mechanisms that allow these cells to persist, the research seeks to develop new therapeutic strategies to eliminate them before they can cause further resistance. This approach could potentially improve the effectiveness of existing cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced non-small cell lung cancer who have tumors with targetable genetic mutations.
Not a fit: Patients without advanced non-small cell lung cancer or those whose tumors do not harbor targetable genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients by preventing the development of drug resistance.
How similar studies have performed: While targeting drug-resistant cancer cells is a novel approach, previous research has shown promise in understanding and addressing mechanisms of drug resistance in cancer treatment.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Janne, Pasi a — Dana-Farber Cancer Inst
- Study coordinator: Janne, Pasi a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.